Literature DB >> 23254140

Gliosarcoma arising from an oligodendroglioma (oligosarcoma).

Annie Hiniker1, Jill M Hagenkord, Martin P Powers, Manish K Aghi, Michael D Prados, Arie Perry.   

Abstract

Gliosarcoma, a biphasic tumor with both mesenchymal and glial elements, is typically considered a variant of astrocytoma (glioblastoma), WHO Grade IV. A 57-year-old man presented with altered mental status and was found to have a large right frontal mass. Biopsy and subsequent subtotal resection revealed a WHO Grade II oligodendroglioma with classic histological features, expression of IDH1 R132H mutant protein, and chromosome 1p19q co-deletion. Fifteen months later, the patient developed recurrent tumor composed of intersecting fascicles of spindled cells with necrosis and a high mitotic index. The recurrent tumor stained for both mesenchymal and glial elements, consistent with the diagnosis of gliosarcoma, and showed retained IDH1 R132H expression. By FISH analysis, the gliosarcoma showed no evidence of 1p19q co-deletion. We performed SNP arrays and detailed SNP analysis of both the oligodendroglioma and the gliosarcoma. This demonstrated loss of heterozygosity (LOH) of chromosomes 1 and 19 in the gliosarcoma with retention of the same full-length chromosomes 1 and 19 found intact in the oligodendroglioma. Not surprisingly, the gliosarcoma harbored multiple additional alterations, consistent with clonal evolution. There have been only rare reports of sarcomatous transformation of oligodendroglioma ("oligosarcoma") and most were published prior to the development of modern genetic modalities. Here we present a case with detailed genetic evidence that suggests that mesenchymal metaplasia sarcomatous transformation is possible in classic oligodendrogliomas with 1p19q codeletions.

Entities:  

Mesh:

Year:  2013        PMID: 23254140     DOI: 10.5414/NP300577

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  6 in total

Review 1.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

2.  Cerebral high-grade oligodendroglioma with sarcomatous transdifferentiation ("oligosarcoma") in a boxer dog.

Authors:  A Fadda; I Vajtai; J Lang; D Henke; A Oevermann
Journal:  J Vet Intern Med       Date:  2014 Nov-Dec       Impact factor: 3.333

3.  Hypermutated phenotype in gliosarcoma of the spinal cord.

Authors:  Christopher S Hong; Gregory A Kuzmik; Adam J Kundishora; Aladine A Elsamadicy; Andrew B Koo; Declan McGuone; Nicholas A Blondin; Michael L DiLuna; E Zeynep Erson-Omay
Journal:  NPJ Precis Oncol       Date:  2021-02-12

4.  Oligosarcomas, IDH-mutant are distinct and aggressive.

Authors:  Christian Hartmann; David E Reuss; Abigail K Suwala; Marius Felix; Dennis Friedel; Damian Stichel; Daniel Schrimpf; Felix Hinz; Ekkehard Hewer; Leonille Schweizer; Hildegard Dohmen; Ute Pohl; Ori Staszewski; Andrey Korshunov; Marco Stein; Thidathip Wongsurawat; Pornsuk Cheunsuacchon; Sith Sathornsumetee; Christian Koelsche; Clinton Turner; Emilie Le Rhun; Angelika Mühlebner; Philippe Schucht; Koray Özduman; Takahiro Ono; Hiroaki Shimizu; Marco Prinz; Till Acker; Christel Herold-Mende; Tobias Kessler; Wolfgang Wick; David Capper; Pieter Wesseling; Felix Sahm; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2021-12-30       Impact factor: 17.088

5.  Recurrent oligodendroglioma with changed 1p/19q status.

Authors:  Valeria Barresi; Andrea Mafficini; Martina Calicchia; Maria Liliana Piredda; Angelo Musumeci; Claudio Ghimenton; Aldo Scarpa
Journal:  Neuropathology       Date:  2022-02-10       Impact factor: 2.076

6.  From astrocytoma to glioblastoma: a clonal evolution study.

Authors:  Fuhua Yang; Yunding Zou; Qiang Gong; Jieping Chen; Wei-Dong Li; Qilin Huang
Journal:  FEBS Open Bio       Date:  2020-03-22       Impact factor: 2.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.